Blood transfusion and survival for resected adrenocortical carcinoma: A study from the United States adrenocortical carcinoma group

American Surgeon

Volumn 83, Issue 7, 2017, Pages 761-768

  Poorman, Caroline E ^a   Postlewait, Lauren M ^a   Ethun, Cecilia G ^a   Tran, Thuy B ^b   Prescott, Jason D ^c   Pawlik, Timothy M ^c   Wang, Tracy S ^d   Glenn, Jason ^d   Hatzaras, Ioannis ^e   Shenoy, Rivfka ^e   Phay, John E ^f   Keplinger, Kara ^f   Fields, Ryan C ^g   Jin, Linda X ^g   Weber, Sharon M ^h   Salem, Ahmed ^h   Sicklick, Jason K ⁱ   Gad, Shady ⁱ   Yopp, Adam C ^j   Mansour, John C ^j   Duh, Quan Yang ^k   Seiser, Natalie ^k   Solorzano, Carmen C ^l   Kiernan, Colleen M ^l   Votanopoulos, Konstantinos I ^m   Levine, Edward A ^m   Staley, Charles A ^a   Poultsides, George A ^b   Maithel, Shishir K ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX CARCINOMA; ADULT; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; HORMONE RELEASE; HUMAN; INFERIOR CAVA VEIN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; OPERATION DURATION; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BLOOD TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 85025803484     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 2013;169:891-9.
2. Margonis GA, Kim Y, Prescott JD, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol 2016;23:134-41.
3. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-26.
4. Livhits M, Li N, Yeh MW, et al. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery 2014;156:1531-40; discussion 1540-1.
5. Margonis GA, Kim Y, Tran TB, et al. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg 2016;211:1106-13.
6. Kim Y, Margonis GA, Prescott JD, et al. Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability. Ann Surg 2017;265:197-204.
7. Postlewait LM, Ethun CG, Tran TB, et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group. J Am Coll Surg 2016;222:480-90.
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology neuroendocrine tumors, 2014. Available at: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp. Accessed February 3, 2016.
9. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115:243-50.
10. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010; 46:713-9.
11. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008;113:3130-6.
12. Bagante F, Tran TB, Postlewait LM, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol 2015;112:164-72.
13. Sutton JM, Kooby DA, Wilson GC, et al. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarci-noma: a multi-institutional study. J Gastrointest Surg 2014;18: 1575-87.
14. Kneuertz PJ, Patel SH, Chu CK, et al. Effects of peri-operative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarci-noma. Ann Surg Oncol 2011;18:1327-34.
15. Squires MH III, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-institution analysis of 765 patients from the US Gastric Cancer Collaborative. J Am Coll Surg 2015;221: 767-77.
16. Asahara T, Katayama K, Itamoto T, et al. Perioperative blood transfusion as a prognostic indicator in patients with hepa-tocellular carcinoma. World J Surg 1999;23:676-80.
17. Sun C, Wang Y, Yao HS, et al. Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg 2015;13:102-10.
18. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;CD005033.
19. Perisanidis C, Dettke M, Papadogeorgakis N, et al. Trans-fusion of allogenic leukocyte-depleted packed red blood cells is associated with postoperative morbidity in patients undergoing oral and oropharyngeal cancer surgery. Oral Oncol 2012;48:372-8.
20. Miki C, Hiro J, Ojima E, et al. Perioperative allogeneic blood transfusion, the related cytokine response and long-term survival after potentially curative resection of colorectal cancer. Clin Oncol (R Coll Radiol) 2006;18:60-6.
21. Postlewait LM, Squires MH 3rd, Kooby DA, et al. The relationship of blood transfusion with peri-operative and long-term outcomes after major hepatectomy for metastatic colorectal cancer: a multi-institutional study of 456 patients. HPB 2015;18: 192-9.
22. Yeh JJ, Gonen M, Tomlinson JS, et al. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exo-crine tumour of the pancreas. Br J Surg 2007;94:466-72.
23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
24. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-13.
25. Wang T, Luo L, Huang H, et al. Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer. Ann Thorac Surg 2014;97:1827-37.
26. Linder BJ, Thompson RH, Leibovich BC, et al. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU Int 2014;114: 368-74.
27. Moriguchi S, Maehara Y, Akazawa K, et al. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer 1990;66:2331-5.
28. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003;237:860-9, discussion 869-70.
29. Foster RS Jr., Foster JC, Costanza MC. Blood transfusions and survival after surgery for breast cancer. Arch Surg 1984;119: 1138-40.
30. Keller SM, Groshen S, Martini N, et al. Blood transfusion and lung cancer recurrence. Cancer 1988;62:606-10.
31. Weiden PL, Bean MA, Schultz P. Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence. Cancer 1987;60:870-4.
32. Chen G, Zhang FJ, Gong M, et al. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B 2007;8: 560-5.
33. Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999;93:1770-7.
34. Innerhofer P, Tilz G, Fuchs D, et al. Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus WBC-reduced blood transfusions in patients undergoing arthroplasty. II. Activation of T cells, macro-phages, and cell-mediated lympholysis. Transfusion 2000;40: 821-7.
35. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253-9.